Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 226, Issue 4, Pages 673-677Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiac235
Keywords
Down syndrome; antibody response; COVID-19 vaccination; SARS-CoV-2
Categories
Funding
- ZonMw, The Netherlands Organization for Health Research and Development [10430072010004]
- Dutch Universities and Academic Hospitals (VSNU)
Ask authors/readers for more resources
Adults with Down syndrome have an increased risk of severe course and mortality from SARS-CoV-2 infection, and this risk persists after vaccination. This study compared the antibody responses to routine SARS-CoV-2 vaccination in adults with Down syndrome and healthy controls, finding lower antibody concentrations in adults with Down syndrome, especially with increasing age.
The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. In this prospective cohort study that included 222 adults with Down syndrome, a significantly lower antibody response was found after SARS-CoV-2 mRNA or vector vaccination compared to healthy controls. After mRNA vaccination, lower antibodies were found with increasing age.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available